Mirum Pharmaceuticals, Inc.

Total Valuation

Mirum Pharmaceuticals, Inc. carries a market capitalization of 4.61B, placing it among publicly traded companies globally. Its enterprise value stands at 4.81B, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.

Share Statistics

Mirum Pharmaceuticals, Inc. currently has 60.93M shares outstanding.

Valuation Ratios

The price-to-sales ratio is 8.56, and the price-to-book ratio stands at -3.34.

Enterprise Valuation

On an enterprise value basis, Mirum Pharmaceuticals, Inc. trades at an EV/EBITDA multiple of 567.73 and an EV/FCF ratio of 360.99.

Financial Position

Mirum Pharmaceuticals, Inc. maintains a current ratio of 2.09, meaning it holds 2.1x the short-term assets needed to cover near-term liabilities. The debt-to-equity ratio is 133.52, indicating elevated leverage, while an interest coverage ratio of -3.13 demonstrates limited ability to service its debt obligations.

Financial Efficiency

Taxes

Stock Price Statistics

Mirum Pharmaceuticals, Inc.'s stock has gained approximately 105.86191% over the past 52 weeks. The 50-day moving average sits at 97.27, while the 200-day moving average is 84.56.

Income Statement

Over the trailing twelve months, Mirum Pharmaceuticals, Inc. generated 569.61M in revenue and converted that into -798.84M in net income, yielding earnings per share of -14.69. EBITDA reached -45.05M, while operating income came in at -70.12M.

Balance Sheet

Mirum Pharmaceuticals, Inc. holds 386.26M in cash and equivalents against 323.78M in total debt, resulting in a net debt position of -14.66M. Total book value stands at -1.46B, with working capital of 296.61M providing operational flexibility.

Cash Flow

Mirum Pharmaceuticals, Inc. produced -170.97M in operating cash flow over the past twelve months. After subtracting -11.58M in capital expenditures, free cash flow totaled -182.55M - equivalent to -3.46 per share.

Margins

Mirum Pharmaceuticals, Inc. operates with a gross margin of 81.39, reflecting its pricing power and cost economics. The operating margin of -12.31 and net profit margin of -140.24 provide insight into operational efficiency.

Dividends & Yields

Scores

Mirum Pharmaceuticals, Inc. posts an Altman Z-Score of 2.40, near the 3.0 threshold that indicates strong financial health and minimal bankruptcy risk.